Trial Outcomes & Findings for JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NCT NCT02706405)
NCT ID: NCT02706405
Last Updated: 2022-08-24
Results Overview
Toxicity graded using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03.
Recruitment status
TERMINATED
Study phase
PHASE1
Target enrollment
30 participants
Primary outcome timeframe
28 days post last infusion of Durvalumab, up to 1 year
Results posted on
2022-08-24
Participant Flow
One patient was enrolled on the trial but did not move on to treatment. They were not assigned to an arm or to a treatment dose level.
Participant milestones
| Measure |
Group I (JCAR014, Durvalumab) Early - Dose Level 2
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - early: start durvalumab no earlier than 7 days after JCAR014.
Group 1 Dose Level 2 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells
|
Group I (JCAR014, Durvalumab) Late- Dose Level 1
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - late: start durvalumab no earlier than 21 days after JCAR014
Group 1 Dose Level 1 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
|
Group I (JCAR014, Durvalumab) Late - Dose Level 2
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - late: start durvalumab no earlier than 21 days after JCAR014
Group 1 Dose Level 2 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells
|
Group II (Durvalumab, JCAR014) - Dose Level 1
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 1 is 7.5 mg Durvalumab, up to 2 x 106/kg CAR T cells
|
Group II (Durvalumab, JCAR014) - Dose Level 2
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 2 is 22.5 mg Durvalumab, up to 2 x 106/kg CAR T cells
|
Group II (Durvalumab, JCAR014) - Dose Level 3
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 3 is 75 mg Durvalumab, up to 2 x 106/kg CAR T cells
|
Group II (Durvalumab, JCAR014) - Dose Level 4
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 4 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
|
Group II (Durvalumab, JCAR014) - Dose Level 5
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 5 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells
|
|---|---|---|---|---|---|---|---|---|
|
Overall Study
STARTED
|
5
|
3
|
3
|
1
|
1
|
3
|
6
|
7
|
|
Overall Study
COMPLETED
|
1
|
1
|
3
|
0
|
1
|
2
|
3
|
1
|
|
Overall Study
NOT COMPLETED
|
4
|
2
|
0
|
1
|
0
|
1
|
3
|
6
|
Reasons for withdrawal
| Measure |
Group I (JCAR014, Durvalumab) Early - Dose Level 2
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - early: start durvalumab no earlier than 7 days after JCAR014.
Group 1 Dose Level 2 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells
|
Group I (JCAR014, Durvalumab) Late- Dose Level 1
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - late: start durvalumab no earlier than 21 days after JCAR014
Group 1 Dose Level 1 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
|
Group I (JCAR014, Durvalumab) Late - Dose Level 2
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - late: start durvalumab no earlier than 21 days after JCAR014
Group 1 Dose Level 2 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells
|
Group II (Durvalumab, JCAR014) - Dose Level 1
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 1 is 7.5 mg Durvalumab, up to 2 x 106/kg CAR T cells
|
Group II (Durvalumab, JCAR014) - Dose Level 2
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 2 is 22.5 mg Durvalumab, up to 2 x 106/kg CAR T cells
|
Group II (Durvalumab, JCAR014) - Dose Level 3
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 3 is 75 mg Durvalumab, up to 2 x 106/kg CAR T cells
|
Group II (Durvalumab, JCAR014) - Dose Level 4
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 4 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
|
Group II (Durvalumab, JCAR014) - Dose Level 5
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 5 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells
|
|---|---|---|---|---|---|---|---|---|
|
Overall Study
Death
|
3
|
2
|
0
|
1
|
0
|
0
|
3
|
4
|
|
Overall Study
Disease progression
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
Overall Study
Pt moved to new therapy
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
1
|
|
Overall Study
Physician Decision
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Baseline Characteristics
JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Baseline characteristics by cohort
| Measure |
Group I (JCAR014, Durvalumab) Early - Dose Level 2
n=5 Participants
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - early: start durvalumab no earlier than 7 days after JCAR014.
Group 1 Dose Level 2 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells
|
Group I (JCAR014, Durvalumab) Late- Dose Level 1
n=3 Participants
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - late: start durvalumab no earlier than 21 days after JCAR014
Group 1 Dose Level 1 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
|
Group I (JCAR014, Durvalumab) Late - Dose Level 2
n=3 Participants
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - late: start durvalumab no earlier than 21 days after JCAR014
Group 1 Dose Level 2 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells
|
Group II (Durvalumab, JCAR014) - Dose Level 1
n=1 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 1 is 7.5 mg Durvalumab, up to 2 x 106/kg CAR T cells
|
Group II (Durvalumab, JCAR014) - Dose Level 2
n=1 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 2 is 22.5 mg Durvalumab, up to 2 x 106/kg CAR T cells
|
Group II (Durvalumab, JCAR014) - Dose Level 3
n=3 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 3 is 75 mg Durvalumab, up to 2 x 106/kg CAR T cells
|
Group II (Durvalumab, JCAR014) - Dose Level 4
n=6 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 4 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
|
Group II (Durvalumab, JCAR014) - Dose Level 5
n=7 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 5 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells
|
Total
n=29 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
2 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
3 Participants
n=8 Participants
|
5 Participants
n=8 Participants
|
4 Participants
n=24 Participants
|
17 Participants
n=42 Participants
|
|
Age, Categorical
>=65 years
|
3 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
1 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
3 Participants
n=24 Participants
|
12 Participants
n=42 Participants
|
|
Sex: Female, Male
Female
|
2 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
1 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
3 Participants
n=24 Participants
|
10 Participants
n=42 Participants
|
|
Sex: Female, Male
Male
|
3 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
1 Participants
n=21 Participants
|
2 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
4 Participants
n=24 Participants
|
19 Participants
n=42 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
4 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
3 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
1 Participants
n=21 Participants
|
3 Participants
n=8 Participants
|
6 Participants
n=8 Participants
|
7 Participants
n=24 Participants
|
28 Participants
n=42 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
1 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
1 Participants
n=42 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
1 Participants
n=42 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
2 Participants
n=42 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=24 Participants
|
1 Participants
n=42 Participants
|
|
Race (NIH/OMB)
White
|
5 Participants
n=5 Participants
|
2 Participants
n=7 Participants
|
3 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
1 Participants
n=21 Participants
|
3 Participants
n=8 Participants
|
4 Participants
n=8 Participants
|
6 Participants
n=24 Participants
|
25 Participants
n=42 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
PRIMARY outcome
Timeframe: 28 days post last infusion of Durvalumab, up to 1 yearToxicity graded using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03.
Outcome measures
| Measure |
Group I (JCAR014, Durvalumab) Early - Dose Level 2
n=5 Participants
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - early: start durvalumab no earlier than 7 days after JCAR014.
Group 1 Dose Level 1 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group I (JCAR014, Durvalumab) Late- Dose Level 1
n=3 Participants
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - late: start durvalumab no earlier than 21 days after JCAR014
Group 1 Dose Level 2 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
.
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group I (JCAR014, Durvalumab) Late - Dose Level 2
n=3 Participants
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - late: start durvalumab no earlier than 21 days after JCAR014
Group 1 Dose Level 2 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 1
n=1 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 1 is 7.5 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 2
n=1 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 2 is 22.5 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 3
n=3 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 3 is 75 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 4
n=6 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 4 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 5
n=7 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 5 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
|---|---|---|---|---|---|---|---|---|
|
Count of Participants Who Experienced Adverse Events
|
5 Participants
|
3 Participants
|
3 Participants
|
1 Participants
|
1 Participants
|
3 Participants
|
6 Participants
|
7 Participants
|
PRIMARY outcome
Timeframe: 28 days post first infusion of Durvalumab (for participants in Group 1) or 28 days post infusion of JCAR (for participants in Group 2)Will be summarized based on the dose limiting toxicity evaluable analysis set. The target toxicity rate for the maximum tolerated dose is 30%. Outcome will be reported as a count of patients in each arm that experienced a DLT.
Outcome measures
| Measure |
Group I (JCAR014, Durvalumab) Early - Dose Level 2
n=5 Participants
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - early: start durvalumab no earlier than 7 days after JCAR014.
Group 1 Dose Level 1 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group I (JCAR014, Durvalumab) Late- Dose Level 1
n=3 Participants
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - late: start durvalumab no earlier than 21 days after JCAR014
Group 1 Dose Level 2 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
.
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group I (JCAR014, Durvalumab) Late - Dose Level 2
n=3 Participants
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - late: start durvalumab no earlier than 21 days after JCAR014
Group 1 Dose Level 2 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 1
n=1 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 1 is 7.5 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 2
n=1 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 2 is 22.5 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 3
n=3 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 3 is 75 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 4
n=6 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 4 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 5
n=7 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 5 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
|---|---|---|---|---|---|---|---|---|
|
Dose Limiting Toxicity (DLT) Rates
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
PRIMARY outcome
Timeframe: 28 daysReporting outcome as the maximum durvalumab dose that we reached on the study. Patients were monitored for 28 days post infusion for dose limiting toxicities. The DLT rate was used to determine dose escalation. The study was terminated prior to reaching the maximum tolerated dose.
Outcome measures
| Measure |
Group I (JCAR014, Durvalumab) Early - Dose Level 2
n=29 Participants
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - early: start durvalumab no earlier than 7 days after JCAR014.
Group 1 Dose Level 1 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group I (JCAR014, Durvalumab) Late- Dose Level 1
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - late: start durvalumab no earlier than 21 days after JCAR014
Group 1 Dose Level 2 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
.
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group I (JCAR014, Durvalumab) Late - Dose Level 2
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - late: start durvalumab no earlier than 21 days after JCAR014
Group 1 Dose Level 2 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 1
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 1 is 7.5 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 2
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 2 is 22.5 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 3
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 3 is 75 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 4
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 4 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 5
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 5 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
|---|---|---|---|---|---|---|---|---|
|
Highest Treatment Dose Administered on Study
|
750 mg
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Up to 12 monthsAbsolute CD4+ and CD8+ CAR-T cell counts were determined by multiplying the percentages of CD3+CD4+CD8-EGFRt+ and CD3+CD4-CD8+EGFRt+ events, respectively, in a viable CD45+ lymphocyte forward/side scatter gate by an absolute lymphocyte count performed on the same day. Excluding 1 patient in Group 2 Dose Level 5 who received an out-of-specification JCAR014 product.
Outcome measures
| Measure |
Group I (JCAR014, Durvalumab) Early - Dose Level 2
n=3 Participants
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - early: start durvalumab no earlier than 7 days after JCAR014.
Group 1 Dose Level 1 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group I (JCAR014, Durvalumab) Late- Dose Level 1
n=8 Participants
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - late: start durvalumab no earlier than 21 days after JCAR014
Group 1 Dose Level 2 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
.
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group I (JCAR014, Durvalumab) Late - Dose Level 2
n=1 Participants
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - late: start durvalumab no earlier than 21 days after JCAR014
Group 1 Dose Level 2 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 1
n=1 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 1 is 7.5 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 2
n=3 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 2 is 22.5 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 3
n=6 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 3 is 75 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 4
n=6 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 4 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 5
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 5 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
|---|---|---|---|---|---|---|---|---|
|
Maximum JCAR014 Cmax by Flow Cytometry
|
201.21 CD3+ CAR-T cells/μL
Interval 9.86 to 555.77
|
13.71 CD3+ CAR-T cells/μL
Interval 1.88 to 36.51
|
8.27 CD3+ CAR-T cells/μL
Interval 8.27 to 8.27
|
3.01 CD3+ CAR-T cells/μL
Interval 3.01 to 3.01
|
13.15 CD3+ CAR-T cells/μL
Interval 3.51 to 32.1
|
18.13 CD3+ CAR-T cells/μL
Interval 5.16 to 51.49
|
7.53 CD3+ CAR-T cells/μL
Interval 1.44 to 13.83
|
—
|
PRIMARY outcome
Timeframe: Up to 28 daysAbsolute CD4+ and CD8+ CAR-T cell counts were determined by multiplying the percentages of CD3+CD4+CD8-EGFRt+ and CD3+CD4-CD8+EGFRt+ events, respectively, in a viable CD45+ lymphocyte forward/side scatter gate by an absolute lymphocyte count performed on the same day. Subjects had samples analyzed at approximately days 0, 3, 7, 10, 14, 21, and 28 after CAR-T cell infusion to generate the AUC from day 0 to 28. The areas under the curve of CAR T-cell counts by flow cytometry and qPCR between time points were calculated by using a trapezoidal rule computational algorithm. Excluding 1 patient in Group 2 Dose Level 5 who received an out-of-specification JCAR014 product.
Outcome measures
| Measure |
Group I (JCAR014, Durvalumab) Early - Dose Level 2
n=3 Participants
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - early: start durvalumab no earlier than 7 days after JCAR014.
Group 1 Dose Level 1 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group I (JCAR014, Durvalumab) Late- Dose Level 1
n=8 Participants
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - late: start durvalumab no earlier than 21 days after JCAR014
Group 1 Dose Level 2 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
.
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group I (JCAR014, Durvalumab) Late - Dose Level 2
n=1 Participants
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - late: start durvalumab no earlier than 21 days after JCAR014
Group 1 Dose Level 2 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 1
n=1 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 1 is 7.5 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 2
n=3 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 2 is 22.5 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 3
n=6 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 3 is 75 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 4
n=6 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 4 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 5
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 5 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
|---|---|---|---|---|---|---|---|---|
|
Area Under the Curve (AUC) of JCAR014 by Flow Cytometry
|
844.77 Days x CD3+ CAR-T cells/μL
Interval 105.13 to 2078.77
|
104.33 Days x CD3+ CAR-T cells/μL
Interval 10.01 to 316.62
|
47.96 Days x CD3+ CAR-T cells/μL
Interval 47.96 to 47.96
|
32.44 Days x CD3+ CAR-T cells/μL
Interval 32.44 to 32.44
|
90.78 Days x CD3+ CAR-T cells/μL
Interval 23.13 to 220.87
|
160.94 Days x CD3+ CAR-T cells/μL
Interval 54.43 to 330.53
|
71.97 Days x CD3+ CAR-T cells/μL
Interval 14.39 to 162.37
|
—
|
PRIMARY outcome
Timeframe: Up to 12 monthsThe number of copies of the CAR transgene/μg of DNA in the blood was determined by using quantitative polymerase chain reaction (qPCR) to detect the integrated Flap-EF1⍺ sequence, with a lower limit of detection of 10 transgene copies/μg of DNA. Excluding 1 patient in Group 2 Dose Level 5 who received an out-of-specification JCAR014 product.
Outcome measures
| Measure |
Group I (JCAR014, Durvalumab) Early - Dose Level 2
n=3 Participants
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - early: start durvalumab no earlier than 7 days after JCAR014.
Group 1 Dose Level 1 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group I (JCAR014, Durvalumab) Late- Dose Level 1
n=8 Participants
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - late: start durvalumab no earlier than 21 days after JCAR014
Group 1 Dose Level 2 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
.
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group I (JCAR014, Durvalumab) Late - Dose Level 2
n=1 Participants
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - late: start durvalumab no earlier than 21 days after JCAR014
Group 1 Dose Level 2 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 1
n=1 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 1 is 7.5 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 2
n=3 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 2 is 22.5 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 3
n=6 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 3 is 75 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 4
n=6 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 4 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 5
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 5 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
|---|---|---|---|---|---|---|---|---|
|
Maximum JCAR014 Cmax in Blood by Quantitative Polymerase Chain Reaction (qPCR) Analysis
|
37647.95 CAR transgene copies/μg DNA
Interval 3699.84 to 97951.33
|
10043.68 CAR transgene copies/μg DNA
Interval 1717.18 to 25286.16
|
3690.24 CAR transgene copies/μg DNA
Interval 3690.24 to 3690.24
|
1949.22 CAR transgene copies/μg DNA
Interval 1949.22 to 1949.22
|
8295.36 CAR transgene copies/μg DNA
Interval 1120.19 to 20755.61
|
27841.31 CAR transgene copies/μg DNA
Interval 1927.33 to 87193.83
|
26297.43 CAR transgene copies/μg DNA
Interval 1515.33 to 122322.41
|
—
|
PRIMARY outcome
Timeframe: Up to 28 daysThe number of copies of the CAR transgene/μg of DNA in the blood was determined by using quantitative polymerase chain reaction (qPCR) to detect the integrated Flap-EF1⍺ sequence, with a lower limit of detection of 10 transgene copies/μg of DNA. Subjects had samples analyzed at approximately days 0, 3, 7, 10, 14, 21, and 28 after CAR-T cell infusion to generate the AUC from day 0 to 28.The areas under the curve of CAR T-cell counts by flow cytometry and qPCR between time points were calculated by using a trapezoidal rule computational algorithm. Excluding 1 patient in Group 2 Dose Level 5 who received an out-of-specification JCAR014 product.
Outcome measures
| Measure |
Group I (JCAR014, Durvalumab) Early - Dose Level 2
n=3 Participants
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - early: start durvalumab no earlier than 7 days after JCAR014.
Group 1 Dose Level 1 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group I (JCAR014, Durvalumab) Late- Dose Level 1
n=8 Participants
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - late: start durvalumab no earlier than 21 days after JCAR014
Group 1 Dose Level 2 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
.
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group I (JCAR014, Durvalumab) Late - Dose Level 2
n=1 Participants
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - late: start durvalumab no earlier than 21 days after JCAR014
Group 1 Dose Level 2 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 1
n=1 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 1 is 7.5 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 2
n=3 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 2 is 22.5 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 3
n=6 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 3 is 75 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 4
n=7 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 4 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 5
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 5 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
|---|---|---|---|---|---|---|---|---|
|
AUC of JCAR014 Cells by qPCR Analysis
|
296188.95 CAR transgene copies/μg DNA x days
Interval 40685.13 to 730201.08
|
104088.38 CAR transgene copies/μg DNA x days
Interval 19729.18 to 433057.46
|
18710.77 CAR transgene copies/μg DNA x days
Interval 18710.77 to 18710.77
|
16721.68 CAR transgene copies/μg DNA x days
Interval 16721.68 to 16721.68
|
63778.63 CAR transgene copies/μg DNA x days
Interval 11246.81 to 155355.19
|
353471.10 CAR transgene copies/μg DNA x days
Interval 27198.84 to 1266668.39
|
389065.24 CAR transgene copies/μg DNA x days
Interval 14387.21 to 1811692.73
|
—
|
PRIMARY outcome
Timeframe: Up to 12 months, +/- 30 daysPopulation: Participants analyzed are the participants with documented loss of detection of JCAR014 in blood by qPCR during follow-up.
The number of copies of the CAR transgene/μg of DNA in the blood was determined by using quantitative polymerase chain reaction (qPCR) to detect the integrated Flap-EF1⍺ sequence, with a lower limit of detection of 10 transgene copies/μg of DNA. Excluding 1 patient in Group 2 Dose Level 5 who received an out-of-specification JCAR014 product.
Outcome measures
| Measure |
Group I (JCAR014, Durvalumab) Early - Dose Level 2
n=2 Participants
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - early: start durvalumab no earlier than 7 days after JCAR014.
Group 1 Dose Level 1 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group I (JCAR014, Durvalumab) Late- Dose Level 1
n=3 Participants
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - late: start durvalumab no earlier than 21 days after JCAR014
Group 1 Dose Level 2 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
.
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group I (JCAR014, Durvalumab) Late - Dose Level 2
n=1 Participants
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - late: start durvalumab no earlier than 21 days after JCAR014
Group 1 Dose Level 2 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 1
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 1 is 7.5 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 2
n=3 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 2 is 22.5 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 3
n=2 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 3 is 75 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 4
n=2 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 4 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 5
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 5 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
|---|---|---|---|---|---|---|---|---|
|
Time to Loss of JCAR014 Detection in Blood by qPCR Analysis
|
113 days
Interval 91.0 to 134.0
|
191 days
Interval 49.0 to 392.0
|
28 days
Interval 28.0 to 28.0
|
—
|
199 days
Interval 168.0 to 227.0
|
183 days
Interval 149.0 to 217.0
|
64 days
Interval 39.0 to 88.0
|
—
|
SECONDARY outcome
Timeframe: Up to 1 yearThis outcome is a count of participants who experienced a best response of complete response (CR) by investigator assessment using Lugano criteria. 1 patient in Group 1 Early Dose Level 2 could not be analyzed for the outcome because they expired before their first response assessment.
Outcome measures
| Measure |
Group I (JCAR014, Durvalumab) Early - Dose Level 2
n=4 Participants
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - early: start durvalumab no earlier than 7 days after JCAR014.
Group 1 Dose Level 1 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group I (JCAR014, Durvalumab) Late- Dose Level 1
n=3 Participants
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - late: start durvalumab no earlier than 21 days after JCAR014
Group 1 Dose Level 2 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
.
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group I (JCAR014, Durvalumab) Late - Dose Level 2
n=3 Participants
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - late: start durvalumab no earlier than 21 days after JCAR014
Group 1 Dose Level 2 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 1
n=1 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 1 is 7.5 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 2
n=1 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 2 is 22.5 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 3
n=3 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 3 is 75 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 4
n=6 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 4 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 5
n=7 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 5 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
|---|---|---|---|---|---|---|---|---|
|
Rate of Complete Response (CR) by Investigator Assessment Using Lugano Criteria
|
1 Participants
|
1 Participants
|
2 Participants
|
0 Participants
|
1 Participants
|
2 Participants
|
2 Participants
|
1 Participants
|
SECONDARY outcome
Timeframe: Up to 1 yearThis outcome is a count of participants who experienced a best response of partial response (PR) by investigator assessment using Lugano criteria. 1 patient in Group 1 Early Dose Level 2 could not be analyzed for the outcome because they expired before their first response assessment.
Outcome measures
| Measure |
Group I (JCAR014, Durvalumab) Early - Dose Level 2
n=4 Participants
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - early: start durvalumab no earlier than 7 days after JCAR014.
Group 1 Dose Level 1 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group I (JCAR014, Durvalumab) Late- Dose Level 1
n=3 Participants
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - late: start durvalumab no earlier than 21 days after JCAR014
Group 1 Dose Level 2 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
.
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group I (JCAR014, Durvalumab) Late - Dose Level 2
n=3 Participants
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - late: start durvalumab no earlier than 21 days after JCAR014
Group 1 Dose Level 2 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 1
n=1 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 1 is 7.5 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 2
n=1 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 2 is 22.5 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 3
n=3 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 3 is 75 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 4
n=6 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 4 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 5
n=7 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 5 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
|---|---|---|---|---|---|---|---|---|
|
Rate of Partial Response (PR) by Investigator Assessment Using Lugano Criteria
|
1 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
SECONDARY outcome
Timeframe: Up to 1 yearORR, defined as a count of participant with a best response of either complete response or partial response. 1 patient in Group 1 Early Dose Level 2 could not be analyzed for the outcome because they expired before their first response assessment.
Outcome measures
| Measure |
Group I (JCAR014, Durvalumab) Early - Dose Level 2
n=4 Participants
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - early: start durvalumab no earlier than 7 days after JCAR014.
Group 1 Dose Level 1 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group I (JCAR014, Durvalumab) Late- Dose Level 1
n=3 Participants
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - late: start durvalumab no earlier than 21 days after JCAR014
Group 1 Dose Level 2 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
.
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group I (JCAR014, Durvalumab) Late - Dose Level 2
n=3 Participants
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - late: start durvalumab no earlier than 21 days after JCAR014
Group 1 Dose Level 2 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 1
n=1 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 1 is 7.5 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 2
n=1 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 2 is 22.5 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 3
n=3 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 3 is 75 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 4
n=6 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 4 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 5
n=7 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 5 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
|---|---|---|---|---|---|---|---|---|
|
Objective Response Rate by Investigator Assessment Using Lugano Criteria
|
1 Participants
|
1 Participants
|
2 Participants
|
0 Participants
|
1 Participants
|
2 Participants
|
2 Participants
|
2 Participants
|
SECONDARY outcome
Timeframe: From first response to progressive disease or death, assessed up to 1 yearPopulation: Total number analyzed will be the patients that progressed or died, excluding those that did not progress or die. 1 patient in Group 1 Early Dose Level 2 could not be analyzed for the outcome because they expired before their first response assessment.
Duration of response will be an average amount of days from first response assessment until progression or death for treated patients. Total number analyzed will be the patients that progressed or died, excluding those that did not progress or die. 1 patient in Group 1 Early Dose Level 2 could not be analyzed for the outcome because they expired before their first response assessment.
Outcome measures
| Measure |
Group I (JCAR014, Durvalumab) Early - Dose Level 2
n=2 Participants
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - early: start durvalumab no earlier than 7 days after JCAR014.
Group 1 Dose Level 1 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group I (JCAR014, Durvalumab) Late- Dose Level 1
n=2 Participants
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - late: start durvalumab no earlier than 21 days after JCAR014
Group 1 Dose Level 2 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
.
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group I (JCAR014, Durvalumab) Late - Dose Level 2
n=2 Participants
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - late: start durvalumab no earlier than 21 days after JCAR014
Group 1 Dose Level 2 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 1
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 1 is 7.5 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 2
n=1 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 2 is 22.5 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 3
n=1 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 3 is 75 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 4
n=4 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 4 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 5
n=7 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 5 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
|---|---|---|---|---|---|---|---|---|
|
Duration of Response
|
72.5 days
Interval 0.0 to 145.0
|
47.5 days
Interval 0.0 to 95.0
|
42 days
Interval 0.0 to 84.0
|
—
|
35 days
Interval 35.0 to 35.0
|
31 days
Interval 31.0 to 31.0
|
97.75 days
Interval 0.0 to 357.0
|
18.14 days
Interval 0.0 to 99.0
|
SECONDARY outcome
Timeframe: From date of first study treatment to progressive disease or death, assessed up to 1 yearOutcome will be reported as a count of those who did not progress and did not die while on study.
Outcome measures
| Measure |
Group I (JCAR014, Durvalumab) Early - Dose Level 2
n=5 Participants
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - early: start durvalumab no earlier than 7 days after JCAR014.
Group 1 Dose Level 1 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group I (JCAR014, Durvalumab) Late- Dose Level 1
n=3 Participants
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - late: start durvalumab no earlier than 21 days after JCAR014
Group 1 Dose Level 2 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
.
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group I (JCAR014, Durvalumab) Late - Dose Level 2
n=3 Participants
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - late: start durvalumab no earlier than 21 days after JCAR014
Group 1 Dose Level 2 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 1
n=1 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 1 is 7.5 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 2
n=1 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 2 is 22.5 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 3
n=3 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 3 is 75 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 4
n=6 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 4 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 5
n=7 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 5 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
|---|---|---|---|---|---|---|---|---|
|
Progression Free Survival
|
2 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
2 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: From date of first study treatment to death, assessed up to 1 yearOutcome will be reported as a count of participants who survived while on study. Survival was assessed up to 1 year.
Outcome measures
| Measure |
Group I (JCAR014, Durvalumab) Early - Dose Level 2
n=5 Participants
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - early: start durvalumab no earlier than 7 days after JCAR014.
Group 1 Dose Level 1 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group I (JCAR014, Durvalumab) Late- Dose Level 1
n=3 Participants
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - late: start durvalumab no earlier than 21 days after JCAR014
Group 1 Dose Level 2 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
.
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group I (JCAR014, Durvalumab) Late - Dose Level 2
n=3 Participants
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - late: start durvalumab no earlier than 21 days after JCAR014
Group 1 Dose Level 2 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 1
n=1 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 1 is 7.5 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 2
n=1 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 2 is 22.5 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 3
n=3 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 3 is 75 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 4
n=6 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 4 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
Group II (Durvalumab, JCAR014) - Dose Level 5
n=7 Participants
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 5 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014: Given IV
Cyclophosphamide: Given IV
Durvalumab: Given IV
Fludarabine: Given IV
|
|---|---|---|---|---|---|---|---|---|
|
Overall Survival
|
2 Participants
|
1 Participants
|
3 Participants
|
0 Participants
|
1 Participants
|
3 Participants
|
3 Participants
|
3 Participants
|
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to 12 monthsOutcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Baseline up to 12 monthsFlow cytometry may be used in the blood, bone marrow, and cerebrospinal fluid (CSF) (if applicable).
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to 12 monthsFlow cytometry may be used in the blood, bone marrow, and CSF (if applicable).
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to 12 monthsOutcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to 12 monthsOutcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to 12 monthsOutcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to 12 monthsOutcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to 12 monthsCellular immune responses to JCAR014 will be considered in patients who have two consecutive negative assays for JCAR014 or who have recovered endogenous B cells. Cellular responses to JCAR014 will be evaluated by assessing reactivity of patient peripheral T cells to JCAR014. Peripheral blood will be collected for these studies.
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to 12 monthsWill be assessed using a validated immunoassay in serum samples.
Outcome measures
Outcome data not reported
Adverse Events
Group I (JCAR014, Durvalumab) Early - Dose Level 2
Serious events: 4 serious events
Other events: 5 other events
Deaths: 3 deaths
Group I (JCAR014, Durvalumab) Late - Dose Level 1
Serious events: 3 serious events
Other events: 3 other events
Deaths: 2 deaths
Group I (JCAR014, Durvalumab) Late - Dose Level 2
Serious events: 2 serious events
Other events: 3 other events
Deaths: 0 deaths
Group II (Durvalumab, JCAR014) - Dose Level 1
Serious events: 1 serious events
Other events: 1 other events
Deaths: 1 deaths
Group II (Durvalumab, JCAR014) - Dose Level 2
Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths
Group II (Durvalumab, JCAR014) - Dose Level 3
Serious events: 2 serious events
Other events: 3 other events
Deaths: 0 deaths
Group II (Durvalumab, JCAR014) - Dose Level 4
Serious events: 4 serious events
Other events: 6 other events
Deaths: 3 deaths
Group II (Durvalumab, JCAR014) - Dose Level 5
Serious events: 4 serious events
Other events: 7 other events
Deaths: 4 deaths
Serious adverse events
| Measure |
Group I (JCAR014, Durvalumab) Early - Dose Level 2
n=5 participants at risk
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - early: start durvalumab no earlier than 7 days after JCAR014.
Group 1 Dose Level 1 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
|
Group I (JCAR014, Durvalumab) Late - Dose Level 1
n=3 participants at risk
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - late: start durvalumab no earlier than 21 days after JCAR014
Group 1 Dose Level 2 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
|
Group I (JCAR014, Durvalumab) Late - Dose Level 2
n=3 participants at risk
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - late: start durvalumab no earlier than 21 days after JCAR014
Group 1 Dose Level 2 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells
|
Group II (Durvalumab, JCAR014) - Dose Level 1
n=1 participants at risk
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 1 is 7.5 mg Durvalumab, up to 2 x 106/kg CAR T cells
|
Group II (Durvalumab, JCAR014) - Dose Level 2
n=1 participants at risk
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 2 is 22.5 mg Durvalumab, up to 2 x 106/kg CAR T cells
|
Group II (Durvalumab, JCAR014) - Dose Level 3
n=3 participants at risk
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 3 is 75 mg Durvalumab, up to 2 x 106/kg CAR T cells
|
Group II (Durvalumab, JCAR014) - Dose Level 4
n=6 participants at risk
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 4 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
|
Group II (Durvalumab, JCAR014) - Dose Level 5
n=7 participants at risk
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 5 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells
|
|---|---|---|---|---|---|---|---|---|
|
General disorders
FEVER
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
General disorders
MULTI-ORGAN FAILURE
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Hepatobiliary disorders
BILE DUCT STENOSIS
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Immune system disorders
CYTOKINE RELEASE SYNDROME
|
40.0%
2/5 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
66.7%
2/3 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
2/6 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Blood and lymphatic system disorders
FEBRILE NEUTROPENIA
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
28.6%
2/7 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Cardiac disorders
SINUS TACHYCARDIA
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Gastrointestinal disorders
ABDOMINAL PAIN
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
66.7%
2/3 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Gastrointestinal disorders
DUODENAL HEMORRHAGE
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
General disorders
DEATH NOS
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Infections and infestations
BACTEREMIA
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Infections and infestations
INFECTIONS AND INFESTATIONS - OTHER, SPECIFY: CENTRAL LINE INFECTION
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Infections and infestations
INFECTIONS AND INFESTATIONS - OTHER, SPECIFY: COAG NEGATIVE STAPHYLOCOCCUS BACTEREMIA
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Infections and infestations
INFECTIONS AND INFESTATIONS - OTHER,SPECIFY: PARAINFLUENZAE VIRUS INFECTION
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Infections and infestations
SEPSIS
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Metabolism and nutrition disorders
ANOREXIA
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
TUMOR PAIN
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Nervous system disorders
ENCEPHALOPATHY
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Nervous system disorders
SOMNOLENCE
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Renal and urinary disorders
HEMATURIA
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Respiratory, thoracic and mediastinal disorders
DYSPNEA
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Respiratory, thoracic and mediastinal disorders
PLEURAL EFFUSION
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Vascular disorders
HYPOTENSION
|
20.0%
1/5 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
Other adverse events
| Measure |
Group I (JCAR014, Durvalumab) Early - Dose Level 2
n=5 participants at risk
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - early: start durvalumab no earlier than 7 days after JCAR014.
Group 1 Dose Level 1 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
|
Group I (JCAR014, Durvalumab) Late - Dose Level 1
n=3 participants at risk
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - late: start durvalumab no earlier than 21 days after JCAR014
Group 1 Dose Level 2 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
|
Group I (JCAR014, Durvalumab) Late - Dose Level 2
n=3 participants at risk
Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
Group 1 - late: start durvalumab no earlier than 21 days after JCAR014
Group 1 Dose Level 2 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells
|
Group II (Durvalumab, JCAR014) - Dose Level 1
n=1 participants at risk
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 1 is 7.5 mg Durvalumab, up to 2 x 106/kg CAR T cells
|
Group II (Durvalumab, JCAR014) - Dose Level 2
n=1 participants at risk
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 2 is 22.5 mg Durvalumab, up to 2 x 106/kg CAR T cells
|
Group II (Durvalumab, JCAR014) - Dose Level 3
n=3 participants at risk
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 3 is 75 mg Durvalumab, up to 2 x 106/kg CAR T cells
|
Group II (Durvalumab, JCAR014) - Dose Level 4
n=6 participants at risk
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 4 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells
|
Group II (Durvalumab, JCAR014) - Dose Level 5
n=7 participants at risk
Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 Dose Level 5 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells
|
|---|---|---|---|---|---|---|---|---|
|
Eye disorders
BLURRED VISION
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Cardiac disorders
SINUS TACHYCARDIA
|
60.0%
3/5 • Number of events 4 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
66.7%
2/3 • Number of events 27 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
66.7%
2/3 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
6/6 • Number of events 13 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
57.1%
4/7 • Number of events 8 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Blood and lymphatic system disorders
ANEMIA
|
40.0%
2/5 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
66.7%
2/3 • Number of events 10 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
3/3 • Number of events 5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
66.7%
4/6 • Number of events 10 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
57.1%
4/7 • Number of events 12 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Blood and lymphatic system disorders
INVESTIGATIONS - OTHER, SPECIFY: INCREASED NUCLEATED RED BLOOD CELLS
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Cardiac disorders
ATRIAL FIBRILLATION
|
20.0%
1/5 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
2/6 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Cardiac disorders
PALPITATIONS
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
2/6 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Cardiac disorders
SINUS BRADYCARDIA
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
3/3 • Number of events 13 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
28.6%
2/7 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Cardiac disorders
SINUS TACHYCARDIA (INTERMITTENT)
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Cardiac disorders
SINUS TACHYCARDIA, INTERMITTENT
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Cardiac disorders
TACHYCARDIA
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Cardiac disorders
VENTRICULAR ARRHYTHMIA
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Ear and labyrinth disorders
EAR AND LABYRINTH DISORDERS - OTHER, SPECIFY: CERUMEN IMPACTION
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Ear and labyrinth disorders
TINNITUS
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Ear and labyrinth disorders
VERTIGO
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Endocrine disorders
ADRENAL INSUFFICIENCY
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Endocrine disorders
HYPOTHYROIDISM
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Eye disorders
CATARACT
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Eye disorders
DRY EYE
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Eye disorders
EYE DISORDERS - OTHER, SPECIFY: PTOSIS
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Eye disorders
FLOATERS
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Gastrointestinal disorders
ABDOMINAL PAIN
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
66.7%
2/3 • Number of events 19 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
66.7%
2/3 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
66.7%
2/3 • Number of events 4 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
2/6 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Gastrointestinal disorders
ABDOMINAL PAIN (AND DISCOMFORT)
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Gastrointestinal disorders
ABDOMINAL PAIN, INTERMITTENT
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Gastrointestinal disorders
ANAL HEMORRHAGE
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Gastrointestinal disorders
BLOATING
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Gastrointestinal disorders
CONSTIPATION
|
40.0%
2/5 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
3/3 • Number of events 9 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
3/3 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
66.7%
2/3 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
83.3%
5/6 • Number of events 6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
57.1%
4/7 • Number of events 9 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Gastrointestinal disorders
CONSTIPATION, INTERMITTENT
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Gastrointestinal disorders
DIARRHEA
|
20.0%
1/5 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
66.7%
2/3 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
66.7%
4/6 • Number of events 5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
28.6%
2/7 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Gastrointestinal disorders
DIARRHEA, INTERMITTENT
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
2/6 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Gastrointestinal disorders
DRY MOUTH
|
40.0%
2/5 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
42.9%
3/7 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Gastrointestinal disorders
DUODENAL HEMORRHAGE
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Gastrointestinal disorders
DYSPEPSIA
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 4 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
50.0%
3/6 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Gastrointestinal disorders
DYSPHAGIA
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Gastrointestinal disorders
DYSPHAGIA (INCREASED)
|
20.0%
1/5 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Gastrointestinal disorders
FECAL INCONTINENCE
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Gastrointestinal disorders
GASTROESOPHAGEAL REFLUX DISEASE
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Gastrointestinal disorders
GASTROINTESTINAL DISORDERS - OTHER, SPECIFY: GASTROESOPHAGEAL REFLUX DISEASE
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Gastrointestinal disorders
GASTROINTESTINAL PAIN
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Gastrointestinal disorders
HEMORRHOIDS
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Gastrointestinal disorders
INJURY, POISONING AND PROCEDURAL COMPLICATIONS - OTHER, SPECIFY: ABDOMINAL TENDERNESS
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Gastrointestinal disorders
INTERMITTENT ABDOMINAL PAIN
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Gastrointestinal disorders
INTERMITTENT DIARRHEA
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Gastrointestinal disorders
MUCOSITIS ORAL
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Gastrointestinal disorders
NAUSEA
|
40.0%
2/5 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
3/3 • Number of events 13 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
66.7%
2/3 • Number of events 4 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
3/3 • Number of events 12 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
83.3%
5/6 • Number of events 8 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
71.4%
5/7 • Number of events 9 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Gastrointestinal disorders
NAUSEA (INTERMITTENT)
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Gastrointestinal disorders
NAUSEA, INTERMITTENT
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Gastrointestinal disorders
STOMACH PAIN
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Gastrointestinal disorders
VOMITING
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
66.7%
2/3 • Number of events 5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
57.1%
4/7 • Number of events 7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Gastrointestinal disorders
VOMITTING
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Gastrointestinal disorders
WORSENING OF CONSTIPATION
|
20.0%
1/5 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
General disorders
BRUISING (INJECTION SITE)
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
General disorders
BRUISING (PICC SITE)
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
General disorders
CHILLS
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
28.6%
2/7 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
General disorders
EDEMA
|
20.0%
1/5 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
General disorders
EDEMA LIMBS
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
66.7%
2/3 • Number of events 10 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
42.9%
3/7 • Number of events 6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
General disorders
EDEMA TRUNK
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
General disorders
FATIGUE
|
80.0%
4/5 • Number of events 17 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
3/3 • Number of events 11 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
3/3 • Number of events 9 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
3/3 • Number of events 11 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
6/6 • Number of events 17 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
85.7%
6/7 • Number of events 20 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
General disorders
FATIGUE (INTERMITTENT)
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
General disorders
FATIGUE, INTERMITTENT
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
General disorders
FEVER
|
40.0%
2/5 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
28.6%
2/7 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
General disorders
FLU LIKE SYMPTOMS
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
General disorders
FLU-LIKE SYMPTOMS
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
General disorders
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS - OTHER, SPECIFY: RIGORS
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
General disorders
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS - OTHER, SPECIFY: COLD SENSATION
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
General disorders
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS - OTHER, SPECIFY: NODULE ON L SOLE
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
General disorders
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS - OTHER, SPECIFY: TROUBLE GETTING WARM
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
General disorders
GENERAL DISORDERS AND SITE ADMINISTRATION SITE CONDITIONS - OTHER, SPECIFY: TIGHTNESS IN CHEST
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
General disorders
GENERALIZED BODY PAIN
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
General disorders
HYPOTHERMIA
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
General disorders
PORT SITE PAIN
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
General disorders
INJURY, POISONING AND PROCEDURAL COMPLICATIONS - OTHER, SPECIFY: HICKMAN LINE RASH
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
General disorders
INJURY, POISONING AND PROCEDURAL COMPLICATIONS - OTHER, SPECIFY: PORT RASH
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
General disorders
INJURY, POISONING AND PROCEDURAL COMPLICATIONS - OTHER, SPECIFY: PORT SITE IRRITATION
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
General disorders
INJURY, POISONING AND PROCEDURAL COMPLICATIONS - OTHER, SPECIFY: REDNESS AT PICC SITE
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
General disorders
MILD ERYTHEMA AND PRURITUS UNDER HICKMAN DRESSING
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
General disorders
INTERMITTENT FEVERS
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
General disorders
MALAISE
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
66.7%
2/3 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
General disorders
METABOLISM AND NUTRITION DISORDERS - OTHER, SPECIFY: EARLY SATIETY
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
General disorders
NON-CARDIAC CHEST PAIN
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
28.6%
2/7 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
General disorders
PAIN
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
General disorders
PORT SITE IRRITATION
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
General disorders
RIGORS
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
General disorders
SKIN AND SUBCUTANEOUS TISSUE DISORDERS - OTHER, SPECIFY: ERYTHEMA AT HICKMAN SITE
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
General disorders
SKIN AND SUBCUTANEOUS TISSUE DISORDERS - OTHER, SPECIFY: HICKMAN LINE RASH
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
General disorders
SKIN AND SUBCUTANEOUS TISSUE DISORDERS - OTHER, SPECIFY: HICKMAN LINE RASH, INTERMITTENT
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
General disorders
SKIN AND SUBCUTANEOUS TISSUE DISORDERS - OTHER, SPECIFY: LINE BANDAGE SITE BLISTER
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
General disorders
SKIN AND SUBCUTANEOUS TISSUE DISORDERS - OTHER, SPECIFY: PICC RASH
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
General disorders
SKIN AND SUBCUTANEOUS TISSUE DISORDERS - OTHER, SPECIFY: PIV RASH
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Hepatobiliary disorders
HEPATOBILIARY DISORDERS - OTHER, SPECIFY: CHOLELITHIASIS
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Hepatobiliary disorders
HEPATOBILIARY DISORDERS - OTHER, SPECIFY: GALLSTONE
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Immune system disorders
CYTOKINE RELEASE SYNDROME
|
40.0%
2/5 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
28.6%
2/7 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Immune system disorders
IMMUNE SYSTEM DISORDERS - OTHER, SPECIFY: HYPOGAMMAGLOBULINEMIA
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Immune system disorders
IMMUNE SYSTEMS DISORDERS- OTHER, SPECIFY: HYPOGAMMAGLOBULINEMIA
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Nervous system disorders
ENCEPHALOPATHY
|
20.0%
1/5 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Infections and infestations
CELLULITIS
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Infections and infestations
ENTEROCOLITIS INFECTIOUS
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Infections and infestations
INFECTIONS AND INFESTATIONS - OTHER, SPECIFY: BACTEREMIA
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Infections and infestations
INFECTIONS AND INFESTATIONS - OTHER, SPECIFY: CENTRAL LINE INFECTION
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Infections and infestations
INFECTIONS AND INFESTATIONS - OTHER, SPECIFY: ORAL THRUSH
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Infections and infestations
INFECTIONS AND INFESTATIONS - OTHER, SPECIFY: PARAINFLUENZA 2
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Skin and subcutaneous tissue disorders
PRURITUS
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Infections and infestations
INFECTIONS AND INFESTATIONS - OTHER, SPECIFY: PARAINFLUENZA 4
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Infections and infestations
INFECTIONS AND INFESTATIONS - OTHER, SPECIFY: RESPIRATORY SYNCYTIAL VIRUS
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Infections and infestations
INFECTIONS AND INFESTATIONS - OTHER,SPECIFY: BACTEREMIA
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Infections and infestations
INJURY, POISONING AND PROCEDURAL COMPLICATIONS - OTHER, SPECIFY: HICKMAN SITE INFECTION
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Infections and infestations
LUNG INFECTION
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Musculoskeletal and connective tissue disorders
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS - OTHER, SPECIFY: HIP BURSITIS
|
20.0%
1/5 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Infections and infestations
MUCOSAL INFECTION
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Infections and infestations
OROPHARANGEAL CANDIDIASIS
|
20.0%
1/5 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Infections and infestations
PAPULOPUSTULAR RASH
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Infections and infestations
PHARYNGITIS
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Infections and infestations
RHINOVIRUS
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Infections and infestations
SEPSIS
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Infections and infestations
SINUSITIS
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Infections and infestations
SKIN INFECTION
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Infections and infestations
UPPER RESPIRATORY INFECTION
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Infections and infestations
URINARY TRACT INFECTION
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
28.6%
2/7 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Infections and infestations
VASCULAR DISORDERS - OTHER, SPECIFY: SEPTIC PULMONARY EMBOLI
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Infections and infestations
WOUND INFECTION
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Injury, poisoning and procedural complications
BRUISING
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
42.9%
3/7 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Injury, poisoning and procedural complications
BRUISING, INTERMITTENT
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Injury, poisoning and procedural complications
DERMATITIS RADIATION
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Injury, poisoning and procedural complications
FALL
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Injury, poisoning and procedural complications
INFECTIONS AND INFESTATIONS - OTHER, SPECIFY: FLEA BITES
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Injury, poisoning and procedural complications
INFUSION RELATED REACTION
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Injury, poisoning and procedural complications
INJURY, POISONING AND PROCEDURAL COMPLICATIONS - OTHER, SPECIFY: BIOPSY SITE PAIN
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Injury, poisoning and procedural complications
INJURY, POISONING AND PROCEDURAL COMPLICATIONS - OTHER, SPECIFY: PAIN AT BIOPSY SITE
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Injury, poisoning and procedural complications
INJURY, POISONING AND PROCEDURAL COMPLICATIONS - OTHER, SPECIFY: PAIN FROM BONE MARROW ASPIRATE
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Injury, poisoning and procedural complications
INJURY, POISONING AND PROCEDURAL COMPLICATIONS - OTHER, SPECIFY: TORN MENISCUS
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Injury, poisoning and procedural complications
INJURY, POISONING, AND PROCEDURAL COMPLICATIONS - OTHER, SPECIFY: CUT ON LEFT FINGER
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Injury, poisoning and procedural complications
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDER - OTHER, SPECIFY: FINGER INJURY
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Injury, poisoning and procedural complications
SKIN AND SUBCUTANEOUS TISSUE DISORDERS - OTHER, SPECIFY: ABRASION
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Investigations
ALANINE AMINOTRANSFERASE INCREASED
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Investigations
ASPARTATE AMINOTRANSFERASE INCREASED
|
20.0%
1/5 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Investigations
BLOOD BILIRUBIN INCREASED
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Investigations
CARDIAC DISORDERS - OTHER, SPECIFY: SYSTOLIC MURMUR
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
2/6 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Investigations
CARDIAC TROPONIN I INCREASED
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Investigations
DECREASED NEUTROPHIL COUNT
|
20.0%
1/5 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Investigations
FIBRINOGEN DECREASED
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Investigations
FIBROGEN COUNT DECREASED
|
20.0%
1/5 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Investigations
INFECTIONS AND INFESTATIONS - OTHER, SPECIFY: ASTROVIRUS TEST POSITIVE
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Investigations
LYMPHOCYTE COUNT DECREASED
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Investigations
NEUTROPHIL COUNT DECREASED
|
40.0%
2/5 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
3/3 • Number of events 8 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
3/3 • Number of events 12 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
3/3 • Number of events 12 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
6/6 • Number of events 14 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
71.4%
5/7 • Number of events 21 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Investigations
PLATELET COUNT DECREASED
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 8 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
57.1%
4/7 • Number of events 17 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Investigations
WEIGHT GAIN
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Investigations
WEIGHT LOSS
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Investigations
WHITE BLOOD CELL DECREASED
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Metabolism and nutrition disorders
ANOREXIA
|
60.0%
3/5 • Number of events 5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
3/3 • Number of events 10 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 4 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
83.3%
5/6 • Number of events 12 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
57.1%
4/7 • Number of events 7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Metabolism and nutrition disorders
ANOREXIA (INTERMITTENT)
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Metabolism and nutrition disorders
ANOREXIA, INTERMITTENT
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Metabolism and nutrition disorders
DEHYDRATION
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Metabolism and nutrition disorders
HYPERGLYCEMIA
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
28.6%
2/7 • Number of events 7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Metabolism and nutrition disorders
HYPERNATREMIA
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Metabolism and nutrition disorders
HYPOALBUMINEMIA
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Metabolism and nutrition disorders
HYPOCALCEMIA
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Metabolism and nutrition disorders
HYPOKALEMIA
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
50.0%
3/6 • Number of events 10 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
42.9%
3/7 • Number of events 4 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Metabolism and nutrition disorders
HYPOMAGNESAEMIA
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Metabolism and nutrition disorders
HYPOMAGNESEMIA
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
50.0%
3/6 • Number of events 6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
28.6%
2/7 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Metabolism and nutrition disorders
HYPONATREMIA
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
2/6 • Number of events 4 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Metabolism and nutrition disorders
HYPOPHOSPHATEMIA
|
20.0%
1/5 • Number of events 4 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Metabolism and nutrition disorders
INVESTIGATIONS - OTHER, SPECIFY: HYPERLIPIDEMIA
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Metabolism and nutrition disorders
INVESTIGATIONS - OTHER, SPECIFY: IRON DEFICIENCY
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Metabolism and nutrition disorders
INVESTIGATIONS -OTHER, SPECIFY: IRON DEFICIENCY
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Metabolism and nutrition disorders
METABOLISM AND NUTRITION DISORDERS - OTHER, SPECIFY: HYPERPHOSPHATEMIA
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Metabolism and nutrition disorders
METABOLISM AND NUTRITION DISORDERS - OTHER, SPECIFY: TYPE 2 DIABETES MELLITUS
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Metabolism and nutrition disorders
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDER - OTHER, SPECIFY: GOUT PAIN
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Metabolism and nutrition disorders
RENAL AND URINARY DISORDERS - OTHER, SPECIFY: GOUT
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Musculoskeletal and connective tissue disorders
ARTHRALGIA
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
66.7%
2/3 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
50.0%
3/6 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Musculoskeletal and connective tissue disorders
ARTHRALGIA, INTERMITTENT
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Musculoskeletal and connective tissue disorders
BACK PAIN
|
60.0%
3/5 • Number of events 6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
66.7%
2/3 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
42.9%
3/7 • Number of events 7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Musculoskeletal and connective tissue disorders
BILATERAL KNEE JOINT PAIN
|
20.0%
1/5 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Musculoskeletal and connective tissue disorders
BONE PAIN
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Musculoskeletal and connective tissue disorders
FLANK PAIN
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
28.6%
2/7 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Musculoskeletal and connective tissue disorders
GENERALIZED MUSCLE WEAKNESS
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
50.0%
3/6 • Number of events 6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
28.6%
2/7 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Musculoskeletal and connective tissue disorders
GENERALIZED MUSCLED WEAKNESS
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Musculoskeletal and connective tissue disorders
LEFT LEG BONE PAIN
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Musculoskeletal and connective tissue disorders
LEFT SHOULDER PAIN
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Musculoskeletal and connective tissue disorders
MUSCULOSKELETAL AND CONNECTIVE TISSUE - OTHER, SPECIFY: LEFT WRIST TENDONITIS
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Musculoskeletal and connective tissue disorders
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDER - OTHER, SPECIFY: RIGHT HIP PAIN
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Musculoskeletal and connective tissue disorders
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS - OTHER, SPECIFY: BACK STIFFNESS
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Musculoskeletal and connective tissue disorders
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS - OTHER, SPECIFY: EXERCISE INDUCED MUSCLE PAIN
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Musculoskeletal and connective tissue disorders
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS - OTHER, SPECIFY: HIP PAIN
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Musculoskeletal and connective tissue disorders
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS - OTHER, SPECIFY: JAW PAIN
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Musculoskeletal and connective tissue disorders
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS - OTHER, SPECIFY: JOINT PAIN DUE TO GARDENING
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Musculoskeletal and connective tissue disorders
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS - OTHER, SPECIFY: MUSCLE SORENESS AFTER ACTIVITY
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Musculoskeletal and connective tissue disorders
NECK PAIN
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Musculoskeletal and connective tissue disorders
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS - OTHER, SPECIFY: MYALGIA AFTER EXERCISE
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Musculoskeletal and connective tissue disorders
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS - OTHER, SPECIFY: RIGHT FOOT PAIN
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Musculoskeletal and connective tissue disorders
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS - OTHER, SPECIFY: SHOULDER PAIN
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Musculoskeletal and connective tissue disorders
MYALGIA
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
2/6 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Musculoskeletal and connective tissue disorders
NECK PAIN, INTERMITTENT
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Musculoskeletal and connective tissue disorders
RIB PAIN
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Musculoskeletal and connective tissue disorders
WORSENING OF LLQ BACK PAIN
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SKIN AND SUBCUTANEOUS SKIN DISORDERS - OTHER, SPECIFY: BASAL CELL LESION
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
TUMOR PAIN
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
2/6 • Number of events 4 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
42.9%
3/7 • Number of events 8 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Nervous system disorders
COGNITIVE DISTURBANCE
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Nervous system disorders
DEPRESSED LEVEL OF CONSCIOUSNESS
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Nervous system disorders
DIZZINESS
|
40.0%
2/5 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
66.7%
2/3 • Number of events 9 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
3/3 • Number of events 6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
2/6 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
42.9%
3/7 • Number of events 6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Nervous system disorders
DIZZINESS (INTERMITTENT)
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Nervous system disorders
DIZZINESS, INTERMITTENT
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
2/6 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Nervous system disorders
DYSARTHRIA
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Nervous system disorders
DYSGEUSIA
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
66.7%
2/3 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Nervous system disorders
EYE DISORDERS - OTHER, SPECIFY: HORNER'S SYNDROME
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Skin and subcutaneous tissue disorders
RASH (BILATERAL FLANKS AND BACK)
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Nervous system disorders
GASTROINTESTINAL DISORDERS - OTHER, SPECIFY: HYPEROSMIA
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Nervous system disorders
HEADACHE
|
40.0%
2/5 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
3/3 • Number of events 4 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
66.7%
4/6 • Number of events 6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
57.1%
4/7 • Number of events 9 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Nervous system disorders
HEADACHE, INTERMITTENT
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Nervous system disorders
HYPERSOMNIA
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Nervous system disorders
INTERMITTENT DIZZINESS
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Nervous system disorders
INTERMITTENT PARESTHESIA
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Nervous system disorders
LETHARGY
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 4 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
28.6%
2/7 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Nervous system disorders
LETHARGY, INTERMITTENT
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Nervous system disorders
MEMORY IMPAIRMENT
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Renal and urinary disorders
URINARY FREQUENCY
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Nervous system disorders
NERVOUS SYSTEM DISORDERS - OTHER, SPECIFY: MIGRAINE
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 10 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Nervous system disorders
NERVOUS SYSTEM DISORDERS - OTHER, SPECIFY: ULNAR NERVE FINGER NUMBESS WITH SHOULDER ABDUCTION
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Nervous system disorders
PARATHESIA
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Renal and urinary disorders
URINARY HESITANCY
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Nervous system disorders
PARESTHESIA
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Nervous system disorders
PERIPHERAL NEUROPATHY
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Nervous system disorders
PERIPHERAL NEUROPATHY (HANDS)
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Nervous system disorders
PERIPHERAL NEUROPATHY, INTERMITTENT
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Nervous system disorders
PERIPHERAL SENSORY NEUROPATHY
|
20.0%
1/5 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
66.7%
2/3 • Number of events 8 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
66.7%
2/3 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
2/6 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
28.6%
2/7 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Nervous system disorders
PERIPHERAL SENSORY NEUROPATHY, INTERMITTENT
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Nervous system disorders
PRESYNCOPE
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Nervous system disorders
SOMNOLENCE
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Nervous system disorders
TREMOR
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
28.6%
2/7 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Nervous system disorders
TREMORS
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Psychiatric disorders
AGITATION
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Psychiatric disorders
ANXIETY
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
66.7%
2/3 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
66.7%
2/3 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
2/6 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
42.9%
3/7 • Number of events 4 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Psychiatric disorders
ANXIETY, INTERMITTENT
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
2/6 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Psychiatric disorders
CONFUSION
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
28.6%
2/7 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Psychiatric disorders
DELIRIUM
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Psychiatric disorders
DEPRESSION
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
2/6 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
42.9%
3/7 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Psychiatric disorders
INSOMNIA
|
40.0%
2/5 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
50.0%
3/6 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
57.1%
4/7 • Number of events 7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Psychiatric disorders
INSOMNIA (INTERMITTENT)
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Psychiatric disorders
INSOMNIA, INTERMITTENT
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Psychiatric disorders
INTERMITTENT ANXIETY
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Psychiatric disorders
INTERMITTENT INSOMNIA
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Psychiatric disorders
PSYCHIATRIC DISORDERS - OTHER, SPECIFY: FLAT AFFECT
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 4 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Psychiatric disorders
RESTLESSNESS
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Renal and urinary disorders
ACUTE KIDNEY INJURY
|
20.0%
1/5 • Number of events 4 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Renal and urinary disorders
DYSURIA
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Renal and urinary disorders
HEMATURIA, INTERMITTENT
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Renal and urinary disorders
RENAL AND URINARY DISORDERS - OTHER, SPECIFY: DYSURIA
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Renal and urinary disorders
RENAL AND URINARY DISORDERS - OTHER, SPECIFY: HYDRONEPHROSIS
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Renal and urinary disorders
RENAL AND URINARY DISORDERS - OTHER, SPECIFY: NOCTURIA
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Renal and urinary disorders
RENAL AND URINARY DISORDERS - OTHER,SPECIFY: NOCTURIA
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Renal and urinary disorders
RENAL CALCULI
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Renal and urinary disorders
URINARY INCONTINENCE
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Renal and urinary disorders
URINARY RETENTION
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Renal and urinary disorders
URINARY TRACT OBSTRUCTION
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Reproductive system and breast disorders
GENITAL EDEMA
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Reproductive system and breast disorders
RENAL AND URINARY DISORDERS - OTHER, SPECIFY: BENIGN PROSTATIC HYPERPLASIA
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Reproductive system and breast disorders
REPRODUCTIVE SYSTEM AND BREAST DISORDERS - OTHER, SPECIFY: NIPPLE PAIN
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Reproductive system and breast disorders
REPRODUCTIVE SYSTEM AND BREAST DISORDERS - OTHER,SPECIFY: VAGINAL BLEEDING
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Reproductive system and breast disorders
VAGINAL DISCHARGE
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Reproductive system and breast disorders
VAGINAL PAIN
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Respiratory, thoracic and mediastinal disorders
ALLERGIC RHINITIS
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Respiratory, thoracic and mediastinal disorders
ALLERGIC RHINITIS, INTERMITTENT
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Respiratory, thoracic and mediastinal disorders
ALLERGIC RHITINITIS, INTERMITTENT
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Respiratory, thoracic and mediastinal disorders
ASPIRATION
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Respiratory, thoracic and mediastinal disorders
ATELECTASIS
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Respiratory, thoracic and mediastinal disorders
COUGH
|
60.0%
3/5 • Number of events 4 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
3/3 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
50.0%
3/6 • Number of events 4 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
28.6%
2/7 • Number of events 4 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Respiratory, thoracic and mediastinal disorders
DSYPNEA
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Respiratory, thoracic and mediastinal disorders
DYSPNEA
|
40.0%
2/5 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
66.7%
2/3 • Number of events 6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
3/3 • Number of events 4 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 4 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
66.7%
4/6 • Number of events 7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
42.9%
3/7 • Number of events 7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Respiratory, thoracic and mediastinal disorders
EPISTAXIS
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
50.0%
3/6 • Number of events 4 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Respiratory, thoracic and mediastinal disorders
HOARSENESS
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Respiratory, thoracic and mediastinal disorders
HYPOXIA
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Respiratory, thoracic and mediastinal disorders
INTERMITTENT COUGH
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Respiratory, thoracic and mediastinal disorders
NASAL CONGESTION
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Respiratory, thoracic and mediastinal disorders
NASAL CONGESTION, INTERMITTENT
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Respiratory, thoracic and mediastinal disorders
PLEURAL EFFUSION
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
2/6 • Number of events 4 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
28.6%
2/7 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Respiratory, thoracic and mediastinal disorders
PNEUMOTHORAX
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Respiratory, thoracic and mediastinal disorders
POST NASAL DRIP
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
66.7%
2/3 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Respiratory, thoracic and mediastinal disorders
POSTNASAL DRIP
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Respiratory, thoracic and mediastinal disorders
PRODUCTIVE COUGH
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Respiratory, thoracic and mediastinal disorders
RESPIRATORY FAILURE
|
20.0%
1/5 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Respiratory, thoracic and mediastinal disorders
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS - OTHER, SPECIFY: TACHYPNEA
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Respiratory, thoracic and mediastinal disorders
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS - OTHER, SPECIFY: BRADYPNEA
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Respiratory, thoracic and mediastinal disorders
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS - OTHER, SPECIFY: HEMOPTYSIS
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Respiratory, thoracic and mediastinal disorders
RHINORRHEA
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Respiratory, thoracic and mediastinal disorders
SORE THROAT
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
50.0%
3/6 • Number of events 5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Respiratory, thoracic and mediastinal disorders
WHEEZING
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
2/6 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Skin and subcutaneous tissue disorders
ALOPECIA
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
2/6 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
28.6%
2/7 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Skin and subcutaneous tissue disorders
BULLOUS DERMITITIS
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Skin and subcutaneous tissue disorders
DIAPHORESIS
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Skin and subcutaneous tissue disorders
DRY SKIN
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
3/3 • Number of events 4 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Skin and subcutaneous tissue disorders
DRY SKIN INTERMITTENT
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Skin and subcutaneous tissue disorders
DRY SKIN, INTERMITTENT
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Skin and subcutaneous tissue disorders
FOREHEAD PRURITIS
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Skin and subcutaneous tissue disorders
RASH ACNEIFORM
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Skin and subcutaneous tissue disorders
RASH MACULOPAPULAR
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Skin and subcutaneous tissue disorders
RASH MACULO-PAPULAR
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
66.7%
2/3 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
2/6 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
28.6%
2/7 • Number of events 4 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Skin and subcutaneous tissue disorders
SKIN AND SUBCUTANEOUS CONDITIONS - OTHER, SPECIFY: LOCALIZED ERYTHEMA OF THE NECK
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Skin and subcutaneous tissue disorders
SKIN AND SUBCUTANEOUS TISSUE DISORDERS - OTHER, SPECIFY: RASH
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Skin and subcutaneous tissue disorders
SKIN AND SUBCUTANEOUS TISSUE DISORDERS - LIVEDO RETICULARIS
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Skin and subcutaneous tissue disorders
SKIN AND SUBCUTANEOUS TISSUE DISORDERS - OTHER, SPECIFY: DIAPHORESIS
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Skin and subcutaneous tissue disorders
SKIN AND SUBCUTANEOUS TISSUE DISORDERS - OTHER, SPECIFY: HEAT RASH
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Skin and subcutaneous tissue disorders
SKIN AND SUBCUTANEOUS TISSUE DISORDERS - OTHER, SPECIFY: INGROWN TOENAIL
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Skin and subcutaneous tissue disorders
SKIN AND SUBCUTANEOUS TISSUE DISORDERS - OTHER, SPECIFY: NIGHT SWEATS
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
2/6 • Number of events 3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Skin and subcutaneous tissue disorders
SKIN AND SUBCUTANEOUS TISSUE DISORDERS - OTHER, SPECIFY: NIGHT SWEATS, INTERMITTENT
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Skin and subcutaneous tissue disorders
SKIN AND SUBCUTANEOUS TISSUE DISORDERS - OTHER, SPECIFY: VENOUS STASIS DERMATITIS
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Skin and subcutaneous tissue disorders
SKIN NODULE
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Skin and subcutaneous tissue disorders
SKIN ULCERATION
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Skin and subcutaneous tissue disorders
VASCULAR DISORDERS - OTHER, SPECIFY: NIGHT SWEATS
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Vascular disorders
FLUSHING
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Vascular disorders
HOT FLASHES
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Vascular disorders
HYPERTENSION
|
60.0%
3/5 • Number of events 6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
66.7%
2/3 • Number of events 4 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
66.7%
2/3 • Number of events 11 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
66.7%
4/6 • Number of events 13 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
71.4%
5/7 • Number of events 16 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Vascular disorders
HYPERTENSION, INTERMITTENT
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Vascular disorders
HYPOTENSION
|
60.0%
3/5 • Number of events 5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
3/3 • Number of events 27 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
66.7%
2/3 • Number of events 2 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
1/1 • Number of events 7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
100.0%
3/3 • Number of events 8 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
83.3%
5/6 • Number of events 12 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
57.1%
4/7 • Number of events 6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Vascular disorders
HYPOTENSION, INTERMITTENT
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Vascular disorders
RIGHT LEG LYMPHEDEMA
|
20.0%
1/5 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/6 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Vascular disorders
SUPERFICIAL THROMBOPHLEBITIS
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Vascular disorders
SUPERIOR VENA CAVA SYNDROME
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/3 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/7 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
|
Vascular disorders
THROMBOEMBOLIC EVENT
|
0.00%
0/5 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
0.00%
0/1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
33.3%
1/3 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
16.7%
1/6 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
14.3%
1/7 • Number of events 1 • 28 days post last infusion of Durvalumab, up to 1 year
An adverse event (AE) is the development of any untoward medical occurrence or the clinical deterioration of a pre-existing medical condition in a patient or clinical study patient administered a medicinal product (e.g., JCAR014 and/or durvalumab). Reporting of AEs will be based on the Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE version 4.03.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place